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CURRENT DATA ON IRON STATUS OFIron deficiency in patients with renal failure. The anemia of
renal failure is caused by the lack of sufficient quantities of DIALYSIS PATIENTS
endogenous erythropoietin. With the availability of recombi-
Two recent studies illustrate the clinician’s problemnant human erythropoietin (rHuEPO), however, it has become
with maintaining adequate available iron in dialysis pa-apparent that to achieve a given target, hematocrit requires
tients. The ESRD National Cooperative Anemia Proj-proper management of iron replacement, as well as the admin-
istration of rHuEPO. Iron deficiency, either absolute or func- ect, mandated by the Health Care Financing Administra-
tional, will occur in most, if not all, patients on hemodialysis tion, examined the cause of a hematocrit of less than 25%
receiving rHuEPO because of the increased demand for iron in a group of hemodialysis patients receiving rHuEPOdriven by the accelerated erythropoiesis that occurs with exoge-
(personal communication, J. Wish, April, 1997). Sixtynous rHuEPO administration, coupled with ongoing blood
percent of patients were found to be iron deficient [de-losses from dialyzer and tubing, blood sampling, gastrointesti-
nal blood loss, and blood losses at the time of dialysis needle fined as a transferrin saturation (Tsat) of less than 20%
placement and removal. Blood loss is less of a problem in and/or a ferritin level of less than 100 ng/ml]. In addition,
patients on peritoneal dialysis, but poor iron intake and in- data recently published by the U.S. Renal Data Systemcreased demand for iron are also seen, the latter in patients
confirm these findings [7]. As part of the Wave 1 of thereceiving rHuEPO. It is essential, therefore, for renal health
Dialysis Morbidity and Mortality Study, 25% of Unitedprofessionals to understand iron metabolism in dialysis patients
in order to properly balance the therapy of renal anemia with States hemodialysis facilities were sampled between Oc-
rHuEPO and supplemental iron. tober and December of 1993. Tsat was less than 20% in
54% of patients and less than 10% in 25% of patients.
Thirty-six percent of patients had a ferritin level of less
Anemia is present in the majority of patients with than 100 ng/ml. Nearly one third of the patients received
chronic renal failure (CRF) on hemodialysis [1, 2]. The no iron supplementation during this time period. The
proximate cause of the anemia is an inadequate quantity clinical significance of these two studies is further empha-
of endogenous erythropoietin (EPO), a 30,400 Dalton sized by the results of the Health Care Financing Admin-
glycoprotein produced by renal tubular cells [3]. Anemia istration Core Indicators Project [8]. This study used data
is typically defined as a level of circulating hemoglobin from 7292 hemodialysis patients randomly selected from
of less than 12 g/dl in women or 14 g/dl in men or an 18 EDRD networks to profile a variety of outcomes,
hematocrit of less than 37% in women or 40% in men [4]. including hematocrit level. In the fourth quarter of 1993,
Because of the introduction of exogenous recombinant only 46% of patients had achieved an hematocrit of more
than 30%. By the fourth quarter of 1995, this numberhuman EPO (rHuEPO) as a therapeutic modality in
had increased to 63%, and a further increase to 72%1989, the character of the anemia in CRF patients has
was seen by the fourth quarter of 1996. The amountundergone significant change [5]. Deficient available iron
of rHuEPO required to achieve these hematocrits wasis the most common cause of initial poor response to
greater in those patients with a low TSAT (J. Wish, per-rHuEPO, as well as acquired refractoriness to this agent
sonal communication).[6]. It is essential, therefore, for renal health profession-
als to understand iron metabolism in dialysis patients in
order to properly balance the therapy of renal anemia
IRON METABOLISM
with rHuEPO and supplemental iron.
Iron is a critical body substance, transporting oxygen
to tissues via hemoglobin and functioning as a cofactor
in a number of enzyme systems [9]. Iron is stored inKey words: anemia, erythropoietin, dialysis, supplemental iron, iron
dextran, iron gluconate, chronic renal failure. reticuloendothelial cells of the liver, spleen, and bone
marrow bound to ferritin and hemosiderin. This storage 1999 by the International Society of Nephrology
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iron constitutes one third of the 3 to 4 g of total body absorption was normal in patients on dialysis [14, 15],
whereas more recent studies using ferrokinetic tech-iron. The remaining iron is present in erythropoietic
tissue or red blood cells (RBCs). The majority of circulat- niques found that uptake of iron by intestinal mucosal
cells and iron retention was decreased significantly ining iron is carried by transferrin, although at any one
time, only 3 to 4 mg of iron are present on transferrin. dialysis patients [10, 16]. High ferritin levels, which can
occur in dialysis patients despite low iron stores, mayIngested iron varies from very small amounts up to 200
mg in end-stage renal disease (ESRD) patients given also impair the normal feedback that would increase
absorption during deficiency states [17]. Further studiessupplements. However, only 1% to 2% of this iron is
absorbed [10]. Internal iron exchange between the ery- are needed to clarify these points.
throid marrow, circulating red blood cells, and the reticu-
External blood lossloendothelial system involves 20 mg or more of iron
daily. In the absence of rHuEPO, patients with advanced There are several factors that contribute to ongoing
blood loss in dialysis patients, including blood retained inrenal disease have less iron exchanged from the erythroid
marrow to RBCs and more stored in the reticuloendo- the dialyzer and blood tubing at the end of each dialysis
treatment, frequent blood testing, occult gastrointestinalthelial system. When the production of RBCs is stimu-
lated by rHuEPO, internal iron exchange in dialysis pa- blood loss, and blood lost from puncturing or removing
needles from hemodialysis vascular accesses [11]. It hastients is similar to that seen in normal patients, although
the reticuloendothelial system may still have a greater been shown that 1 to 3 g of iron are lost annually from
these causes [18]. It should be kept in mind that theretention of iron than seen in patients with normal renal
function. higher the hematocrit achieved with rHuEPO, the greater
the iron loss with each milliliter of lost blood, because
of the higher percentage of RBCs containing iron that
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are lost at a higher hematocrit [11]. The Anemia Work
PATHOGENESIS
Group of the Dialysis Outcomes Quality Initiative sug-
There are three important mechanisms that have been gested that 25 to 100 mg of iron would need to be replaced
proposed to explain the high frequency of iron deficiency weekly in hemodialysis patients just to offset the iron lost
in dialysis patients, in addition to the increased demand because of the ongoing external blood losses described
for iron and consequent storage in RBCs when erythro- earlier here [19]. There are no data available on the
poiesis is stimulated with rHuEPO. These include abnor- external blood losses that occur in peritoneal dialysis
mal iron absorption, external blood loss, and functional patients. Clearly, the lack of blood loss in the dialyzer
iron deficiency [11]. and tubing, the absence of needle sticks, and heparin
use would lead one to predict a substantially smaller
Iron absorption in dialysis patients blood loss in this patient population. For those peritoneal
Absorption of iron from the gastrointestinal tract is dialysis patients receiving rHuEPO, however, the in-
modulated by the level of body iron stores, EPO, and creased demand for iron, as erythropoiesis is stimulated
the extent of erythropoiesis [12]. Iron absorption takes by rHuEPO, will still need to be addressed [20, 21].
place almost exclusively in the duodenum and proximal
Functional iron deficiencyjejunum and is regulated depending on dietary intake,
intraluminal factors, erythropoietic activity, the func- A further complicating feature in the management or
tional capacity of the intestinal mucosal cells, and the identification of iron deficiency in the dialysis population
tissue-iron storage level [13]. Ingested iron is reduced to is the introduction of the concept of functional iron defi-
the ferrous form and is bound to high molecular weight ciency [22, 23]. Functional iron deficiency is present when
chelators. Red meat contains primarily heme iron, which the usual tests for iron deficiency in dialysis patients do
is more avidly absorbed [13]. Restrictions in the ingestion not indicate absolute iron deficiency (ferritin of more
of red meat, common in dialysis patients, may account, than 100 ng/ml; Tsat of more than 20%), but patients
in part, for the small amount of iron that is absorbed in respond to additional iron administration with a rise in
this population. It should be noted that the proportion hematocrit at a stable EPO dose or maintain a stable
of ingested iron absorbed in individuals with normal hematocrit with a lower EPO dose. Patients with func-
renal function is also low, with 1 mg of iron or less tional iron deficiency therefore have apparently insuffi-
absorbed daily. On the other hand, iron absorption gen- cient available iron to keep up with the demands of
erally increases in the face of accelerated erythropoiesis the stimulated erythropoiesis that occur when exogenous
or a decrease in body iron stores [12]. Conflicting data EPO is administered [24].
have appeared in the literature regarding the balance of In some such patients, the inability to mobilize iron
these factors in influencing iron absorption in dialysis rapidly relates to the presence of reticuloendothelial
blockade [25]. Dialysis patients may have coexisting oc-patients [10, 14–16]. Early studies suggested that iron
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cult infections or other conditions that may preclude an and serum ferritin levels are low. A Tsat below 10% is
diagnostic, although a value lower than 16% is highlyappropriate response to iron therapy or prevent the use
of iron stores that would otherwise be sufficient to sustain suggestive of iron deficiency. In iron deficiency uncom-
plicated by dialysis or CRF, serum ferritin levels of lessadditional erythropoiesis. This effect may be caused by
increased levels of circulating cytokines that are capable than 10 ng/ml are considered diagnostic of iron defi-
ciency, and values of less than 20 ng/ml are suggestiveof inducing macrophages of the reticuloendothelial sys-
tem to more avidly take up and hold on to iron. The of a deficient state [17, 35]. Transferrin is the protein
responsible for transfer of iron to the reticuloendothelialeffect of cytokines may involve a decrease in endogenous
EPO production or a decrease in responsiveness of ery- system and iron storage sites to the erythroid marrow.
Low saturations are indicative of both (a) an increasethroid precursor cells to endogenous or exogenous EPO.
In particular, interleukin-1b (possibly acting through in- in total transferrin concentration and synthesis that is
increased under autoregulation by iron deficiency andterferon-g) and tumor necrosis factor-a have been shown
to have both of these effects [26–29]. In addition, in- (b) a low percentage of total circulating iron occupying
available transferrin-binding sites [17, 35]. Iron storedterleukin-6 has recently been shown to decrease respon-
siveness to EPO as well [30]. Such patients typically have in the liver and other tissues is present in the form of
intracellular ferritin. Serum ferritin levels are known tohigh Tsat levels and elevated levels of serum ferritin.
Iron therapy in these patients, unlike other patients with bear a positive correlation with intracellular ferritin iron
stores.functional iron deficiency, generally will not produce a
favorable response. The only current method of separat- Historically, serum ferritin was thought to increase
when intracellular ferritin levels were high, so that highing the two groups is a therapeutic trial of exogenous
iron. Therapeutic trials in such patients should therefore serum ferritin levels were indicative of intracellular ferri-
tin concentration or intracellular stores. Two lines ofclosely monitor subsequent ferritin, Tsat, and hematocrit
levels. evidence challenge this thesis. First, intracellular ferritin
appears to be a completely different protein species than
circulating serum ferritin [36]. The theory that serumIRON DEFICIENCY IN DIALYSIS PATIENTS:
ferritin represents a “leakage” of intracellular ferritinDIAGNOSIS AND IMPACT ON
when the levels of the latter are high is therefore untena-rHuEPO RESPONSE
ble. Second, serum ferritin is also known to increase
Inadequate iron availability, either because of abso- nonspecifically as an acute phase reactant. Many chronic
lute or functional iron deficiency, is now the most com- diseases, including CRF, are associated with spuriously
mon yet easily treatable cause of a suboptimal response high serum ferritin levels notwithstanding low tissue iron
to rHuEPO [31, 32]. Iron-deficiency anemia results from levels.
the absence of sufficient stores of iron within the body
to sustain hematopoiesis. As noted earlier here, iron
SUMMARY AND CONCLUSIONSis present in circulating RBCs and myoglobin, in the
erythroid marrow, and in longer term storage sites, such Proper management of iron status in dialysis patients
should improve patient outcomes by helping assure thatas the liver and macrophages within the reticuloendothe-
lial system. Thus, although iron deficiency anemia is inde- patients can achieve a selected target hematocrit using
a reasonable amount of rHuEPO. A thorough under-pendent, in terms of etiology, from the anemia that re-
sults from EPO deficiency, the two causes of anemia standing of iron metabolism and iron deficiency is essen-
tial so that the clinician can correctly identify those pa-frequently coexist because of the effects of EPO on iron
store mobilization [33]. Administration of rHuEPO, tients who would benefit from iron therapy, and so that
he or she can guide the most efficient and effective meth-therefore, may further expose or exacerbate underlying
iron deficiency, particularly in the hemodialysis popula- ods of iron administration. Currently, in the United
States, iron dextran is the only parenteral iron prepara-tion, which suffers ongoing substantial blood loss [34].
It should be noted, however, that there are no recent tion available. Sodium ferric gluconate complex in su-
crose, which reportedly is associated with less seriousstudies available on hemodialysis-related blood loss in
which patients are dialyzed with hollow fiber dialyzers, side-effects than iron dextran, may soon be available in
the United States as well. Recently, North Americansituations where heparin can be used more sparingly,
and now that dialyzer reprocessing is prevalent. Such clinical trials have demonstrated its safety and efficacy.
The likelihood of serious allergic reactions may be sig-studies are needed.
Although the diagnosis of iron deficiency in dialysis nificantly reduced with this compound, and it has been
used successfully in patients who are allergic to ironpatients is discussed in detail elsewhere in this issue, a
few points are important to emphasize. Iron deficiency dextran [37, 38].
Future research is needed to clarify unanswered ques-is generally accepted as being present when both Tsat
Nissenson and Strobos: Iron deficiency in renal failure S-21
ysis patients treated with erythropoietin. Clin Invest Med 14:271–tions regarding iron absorption in dialysis patients, in-
276, 1991
cluding: determining the most accurate tests to identify 17. Bridges KR, Seligman PA: Disorders of iron metabolism, in
Blood: Principles and Practice of Hematology, edited by Handinpatients with absolute and functional iron deficiency, the
RI, Lux SE, Stossel TP, New York, Lippincott, 1995relative safety and efficacy of parenteral iron com- 18. Akmal M, Sawelson S, Karubian F, Gadallah M: The preva-
pounds, the clinical significance of elevated ferritin levels lence and significance of occult blood loss in patients with predial-
ysis advanced chronic renal failure, or receiving dialytic therapy.in CRF patients, and the potential harm, if any, of overly
Clin Nephrol 42:198–202, 1994aggressive iron repletion in this patient population [39]. 19. NKF-DOQI clinical practice guidelines for hemodialysis adequacy.
Am J Kidney Dis 30:S192–S236, 1997By carefully balancing iron administration with adjust-
20. Johnson CA, Rosowski SW, Zimmerman SW: A prospective open-ments in rHuEPO dosage, clinicians can maximize pa-
label study evaluating the efficacy and adverse reactions of the use
tient outcomes while minimizing complications and cost, of Niferex-150 in ESRD patients receiving EPOGEN. Adv Perit
Dial 8:444–447, 1992and thus achieve what should be the primary goal of
21. Suh H, Wadhwa NK: Iron dextran treatment in peritoneal dialysisESRD therapy: improved patient quality of life and patients on erythropoietin. Adv Perit Dial 8:464–466
treatment satisfaction, along with a decrease in mortality 22. Eschbach J, Egrie J, Downing M: Correction of anemia of end
stage renal disease with recombinant human erythropoietin. Nand morbidity.
Engl J Med 316:73–78, 1987
23. Eschbach J: Erythropoietin 1991: An overview. Am J Kidney Dis
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E-mail: anissens@medicine.medsch.ucla.edu tients treated with erythropoietin. Erythropoiesis 3:50–55, 1992
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